Introduction: The progressive dementia that is characteristic of Alzheimer's disease is associated with the accumulation of amyloid-beta (Aβ) peptides in extracellular plaques and within neurons. Aβ peptides are targeted to cholesterol-rich membrane micro-domains called lipid rafts. Observations that many raft proteins undertake recycling pathways that avoid the lysosomes suggest that the accumulation of Aβ in neurons may be related to Aβ targeting lipid rafts. Here we tested the hypothesis that the degradation of Aβ by neurons could be increased by drugs affecting raft formation.
Introduction
The amyloid hypothesis of Alzheimer's disease (AD) pathogenesis maintains that the primary event is the production of specific C-terminal amyloid-beta (Aβ) peptides following the abnormal proteolytic cleavage of the amyloid precursor protein [1] . Aβ oligomers demonstrate diseasespecific accumulation in human brain and cerebrospinal fluid [2] . The accumulation of Aβ peptides leads to the subsequent disruption of neuronal processes, abnormal phosphorylation of tau [3] , and synapse degeneration [4] . Currently, soluble Aβ 42 oligomers are regarded as potent neurotoxins [5, 6] .
Neurodegeneration is preceded by the intraneuronal accumulation of Aβ [7, 8] . The chronic nature of AD suggests that it is a slow accumulation of Aβ that triggers neurodegeneration and hence the clinical symptoms. Whereas the factors that affect the production of the Aβ have been studied extensively, the capacity of neurons to degrade Aβ once it has been formed has received less attention. Thus, the accumulation of Aβ within neurons may result from a slow rate of degradation. Aβ peptides can be degraded by proteases, including neprilysin [9] , insulysin [10] , cathepsin B [11] , and acyl peptide hydrolase [12] . The observation that Aβ was degraded more quickly in microglial cells than in neurons (unpublished data) raised the question of whether the rate of degradation of Aβ within neurons could be increased.
Studies that use synthetic Aβ preparations may be compromised by their propensity to self-aggregate into a wide variety of oligomer sizes and conformations. The polymorphic nature of Aβ aggregates suggests that there exist disease-relevant conformations of Aβ but that other conformations are less toxic [13, 14] . It is difficult to control the size and conformation of synthetic Aβ 42 oligomers in aqueous medium and consequently it is not clear which of the Aβ conformations are responsible for specific biological properties. To overcome this problem, conditioned media from 7PA2 cells (7PA2-CM) which contain naturally secreted Aβ oligomers [15] were used in this study. The Aβ oligomers secreted by these cells are sodium dodecyl sulphate (SDS)-stable, as are the Aβ oligomers found within the cerebrospinal fluid of patients with AD [16] [17] [18] . Although 7PA2-CM includes other amyloid precursor protein (APP) metabolites, including Aβ 40 and p3, we decided to specifically measure Aβ 42 peptides because of the close association of this isoform with disease.
Aβ 42 peptides are found in detergent-resistant, cholesteroldense membrane micro-domains which are commonly referred to as rafts [19] [20] [21] . Since many raft-associated proteins traffic through cells via recycling pathways that avoid the lysosomes [22, 23] , we hypothesized that the targeting of Aβ 42 to rafts caused it to avoid the lysosomes and degradation. Thus, the targeting of Aβ 42 to rafts may contribute to their gradual accumulation within neurons and subsequently their toxic effects. In this study, non-toxic concentrations of Aβ 42 were taken up by cultured neurons and targeted to detergent-resistant membranes (DRMs) (lipid rafts). As a consequence, it was slowly degraded and had a half-life of greater than 5 days. As the formation and function of lipid rafts is dependent upon the amount of cholesterol within cell membranes [24] [25] [26] , the effects of the cholesterol synthesis inhibitor squalestatin [27] on the cellular targeting of Aβ 42 were studied. Here, we show that, in neurons treated with squalestatin, significantly less Aβ 42 was targeted to rafts and more was found within lysosomes. Consequently, in squalestatin-treated neurons, the half-life of Aβ 42 was reduced to less than 24 hours. Such results indicate that the pharmacological manipulation of neurons can alter the clearance of Aβ 42 .
Methods

Primary neuronal cultures
Cortical neurons were prepared from the brains of mouse embryos (day 15.5). Neurons were plated at 10 6 cells per well in six-well plates in Ham's F12 containing 5% fetal calf serum for 2 hours. Cultures were shaken (600 rpm for 5 minutes), and non-adherent cells were removed by two washes in phosphate-buffered saline (PBS). Neurons were subsequently grown in neurobasal medium containing B27 components supplemented with 5 nM brain-derived nerve growth factor for 10 days. Immunohistochemistry showed that the cells were greater than 95% neurofilamentpositive. Less than 3% stained for glial fibrillary acidic protein (astrocytes) or for F4/80 (microglial cells). Neurons were pre-treated with test compounds for 3 hours before the addition of Aβ preparations, and the amount of Aβ 42 in treated neurons was measured at specific time points thereafter. All experiments were performed in accordance with European regulations (European community Council Directive, 1986, 56/609/EEC) and approved by the Royal Veterinary College ethics committee.
Cell extracts
Neurons were washed twice with PBS and homogenized in a buffer containing 10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 10 mM EDTA, 0.5% Nonidet P-40, 0.5% sodium deoxycholate, 0.2% SDS, and mixed protease inhibitors (4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF), Aprotinin, Leupeptin, Bestatin, Pepstatin A, and E-46) (Sigma-Aldrich, St. Louis, MO, USA) at 10 6 cells/mL. Nuclei and large fragments were removed by centrifugation (300 g for 5 minutes).
Isolation of detergent-resistant membranes
These membranes were isolated by their insolubility in non-ionic detergents as described [28] . Briefly, cells were homogenized in an ice-cold buffer containing 1% Triton X-100, 10 mM Tris-HCl, pH 7.2, 150 mM NaCl, 10 mM EDTA, and mixed protease inhibitors at 10 6 cells/mL, and nuclei and large fragments were removed by centrifugation (300 g for 5 minutes at 4°C). The post-nuclear supernatant was incubated on ice (4°C) for 1 hour and centrifuged (16,000 g for 30 minutes at 4°C). The supernatant was reserved as the detergent-soluble membrane; the insoluble pellet was homogenized in an extraction buffer containing 10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 10 mM EDTA, 0.5% Nonidet P-40, 0.5% sodium deoxycholate, 0.2% SDS, and mixed protease inhibitors at 10 6 cells/mL and was centrifuged (10 minutes at 16,000 g); and the soluble material was reserved as the DRM fraction.
Sucrose density isolation
Neurons were harvested with a Teflon scraper and collected at 800 g for 5 minutes. Cell pellets were homogenized in a buffer containing 250 mM sucrose, 10 mM Tris-HCl (pH 7.4), 1 mM EGTA, mixed protease inhibitors, and 1 mM dithiothreitol at 10 6 cells/mL. Particulate membrane fragments and nuclei were removed by centrifugation (1,000 g for 5 minutes). Membranes were washed by centrifugation at 16,000 g for 10 minutes at 4°C and suspended in an ice-cold buffer containing 1% Triton X-100, 10 mM Tris-HCl pH 7.2, 150 mM NaCl, 10 mM EDTA. Sucrose solutions of 5%, 10%, 15%, 20%, 25%, 30%, and 40% were prepared and layered over each other. Solubilized membranes were added on top and centrifuged at 50,000 g for 18 hours at 4°C. Serial 1-mL aliquots were collected from the bottom of gradients.
Isolation of lysosomes
Lysosomes were isolated by using a lysosome enrichment kit designed for cultured cells in accordance with the instructions of the manufacturer (Pierce, Rockford, IL, USA). Briefly, treated cells were collected and homogenized in ice-cold lysosome enrichment reagents containing protease inhibitors (as above). The cell extract was overlaid on a discontinuous density gradient prepared from OptiPrep™ media and centrifuged at 145,000 g for 2 hours at 4°C. Serial 1-mL aliquots were collected from the bottom of gradients. The lysosome fraction was collected, washed three times in PBS (18,000 g for 30 minutes at 4°C), and solubilized in an extraction buffer containing 10 mM Tris-HCl pH 7.4, 100 mM NaCl, 10 mM EDTA, 0.5% Nonidet P-40, 0.5% sodium deoxycholate, 0.2% SDS, and protease inhibitors (as above). Samples were mixed with an equal volume of Laemmli buffer, boiled, and subjected to electrophoresis on a 15% polyacrylamide gel. Proteins were transferred onto a Hybond-P polyvinylidiene fluoride (PVDF) membrane by semi-dry blotting. Membranes were blocked by using 10% milk powder in PBS containing 0.2% Tween 20. Blots were probed with anti-lysosome-associated membrane protein 1 (LAMP-1) (Pharmingen, San Diego, CA, USA) followed by peroxidase-labelled anti-rabbit antibodies and visualized by using enhanced chemiluminescence.
Isolation of endoplasmic reticulum
Endoplasmic reticulum (ER) fractions were isolated from treated cells by using an ER preparation kit (Sigma-Aldrich) in accordance with the instructions of the manufacturer. Homogenized cell extracts were separated on a discontinuous density gradient (OptiPrep™). Serial 1-mL aliquots were collected from the bottom of gradients. Fractions were diluted 1:20 in carbonate buffer and distributed into Nunc Maxisorp immunoplates (Nunc, Roskilde, Denmark) overnight. Plates were blocked with 5% milk powder and probed with monoclonal antibody (mAb) reactive to the ER marker Grp 78 (Stressgen Biotechnology, Victoria, Canada), polyclonal anti-PAF receptor (Cayman Chemical Company, Ann Arbor, MI, USA), anti-cholesterol ester hydrolase (CEH) (LifeSpan BioSciences, Seattle, WA, USA), or anti-acylcoenzyme A:cholesterol acyltransferase (ACAT) (Abcam, Cambridge, UK), followed by biotinylated anti-rabbit IgG (Sigma-Aldrich), extravidin-alkaline phosphatase (SigmaAldrich), and the addition of the substrate p-nitrophenyl phosphate (p-NPP), 1 ng/mL, diluted in diethanolamine buffer. Optical density was read in a spectrophotometer at 405 nm.
Cholesterol and protein content
Protein concentrations were measured by using a micro-BCA protein assay kit (Pierce). The amount of cholesterol was measured by using the Amplex Red cholesterol assay kit (Invitrogen, Carlsbad, CA, USA). Cholesterol was oxidized by cholesterol oxidase to yield hydrogen peroxide and ketones. The hydrogen peroxide reacts with 10-acetyl-3, 7-dihydroxyphenoxazine (Amplex Red) to produce highly fluorescent resorufin, which is measured by excitation at 550 nm and emission detection at 590 nm. Samples were incubated in the presence or absence of cholesterol esterase to determine the amounts of esterified cholesterol.
Drugs
Arachidonyl trifluoromethyl ketone (AACOCF 3 ), acetyl salicylic acid, diethylumbelliferyl phosphate (DEUP), ginkgolide B, ibuprofen, platelet-activating factor (PAF), 1-O-Hexadecyl-2-acetyl-sn-glycerol-3-phospho-(N,N,N-trimethyl)-hexanolamine (Hexa-PAF), methyl arachidonyl fluorophosphonate (MAFP), acetyl salicylic acid, ibuprofen, simvastatin, and squalene were all obtained from Sigma-Aldrich. Squalestatin was a gift from GlaxoSmithKline (Uxbridge, Middlesex, UK). Stock solutions were dissolved in ethanol or di-methyl sulphoxide and diluted in medium to obtain final working concentrations. Vehicle controls consisted of equivalent dilutions of ethanol or dimethyl sulphoxide in culture medium.
Preparation of Aβ-containing medium
Conditioned media (CM) from Chinese hamster ovary (CHO) cells stably transfected with a cDNA encoding APP 751 (referred to as 7PA2 cells) was cultured in Dulbecco's modified Eagle's medium with 10% fetal calf serum as described [15] . CM from these cells contains stable Aβ (7PA2-CM). 7PA2-CM was centrifuged at 100,000 g for 4 hours at 4°C to remove cell debris and then passed through a 50-kDa filter (Sartorius, Goettingen, Germany) before use. To demonstrate Aβ species, concentrated 7PA2-CM was mixed 1:1 with (0.5% NP-40, 5 mM CHAPS, 50 mM Tris-HCl, pH 7.4, and mixed protease inhibitors) and separated by polyacrylamide gel electrophoresis (PAGE) under non-denaturing conditions. Proteins were transferred onto a Hybond-P PVDF membrane (Amersham Biotech, now part of GE Healthcare, Little Chalfont, Buckinghamshire, UK) by semi-dry blotting. Membranes were blocked by using 10% milk powder and incubated with mAb 6E10 reactive with amino acids 1 to 16 of human Aβ (Signet, part of Covance, Princeton, NJ, USA). Bound mAbs were detected with biotinylated anti-mouse IgG, extravidin-peroxidase, and enhanced chemiluminescence.
Size exclusion chromatography
7PA2-CM or brain extracts were concentrated by desalting columns (3-kDa filter; Sartorius) and injected into a Superdex 75 PC column (separates peptides ranging from 3 to 70 kDa) (GE Healthcare) and eluted at a rate of 0.2 mL/minute. Fractions were collected and tested by Aβ enzyme-linked immunosorbent assay (ELISA) (see below).
Sample preparation
To detach Aβ 42 from cellular binding proteins that could occlude specific epitopes, cell extracts (200 μL) were mixed with 500 μL of 70% formic acid and sonicated. A 50-μL aliquot was added to 450 μL of 1 M Tris-HCl with protease inhibitors (as above) and sonicated before addition to ELISA.
Synthetic Aβ
A peptide corresponding to amino acids 1 to 42 of Aβ (Aβ ) was obtained from Bachem (Bubendorf, Switzerland) and dissolved in hexafluoroisopropanol, lyophilized, and stored at −80°C. On the day of use, it was dissolved in dimethylsulphoxide at 1 mM, diluted in culture medium, and sonicated prior to addition to cells.
Aβ 42 enzyme-linked immunosorbent assay
Nunc Maxisorp immunoplates were coated with mAb 4G8 (epitope 17-24) (Covance) in carbonate buffer overnight. Plates were blocked with 5% milk powder in PBS-tween, and samples were applied. The detection antibody was an Aβ 42 selective rabbit mAb BA3-9 (Covance) followed by biotinylated anti-rabbit IgG (Sigma-Aldrich). Total Aβ was visualized by addition of the substrate (pNPP) 1 ng/mL, diluted in diethanolamine buffer, and optical density was read in a spectrophotometer at 405 nm.
Statistical methods
Differences between treatment groups were assessed by using Student t tests.
Results
Squalestatin increased the degradation of Aβ 42
The amount and distribution of cholesterol are recognized as factors that affect the progression of AD [29, 30] . As squalestatin reduced the cholesterol content of cultured neurons [31] , the fate of Aβ 42 in squalestatin-treated neurons was examined. Treatment with 200 nM squalestatin for 24 hours reduced the cholesterol content of neurons from 519 ng cholesterol/10 6 cells ± 48 to 369 ng ± 66, n = 6, P <0.05, without affecting neuronal viability as measured by thiazolyl blue tetrazolium (MTT). Both treated and untreated neurons were subsequently incubated with 7PA2-CM containing 10 nM Aβ 42 , a mixture of monomers, dimers, trimers, and tetramers as shown in Figure 1A . An analysis of concentrated 7PA2-CM by size exclusion chromatography also showed that it contained three main peaks corresponding to monomers, dimers, and trimers ( Figure 1B ). The concentrations of Aβ 42 used did not affect neuronal survival during the 5-day incubation period. In control neurons, Aβ 42 had a half-life of greater than 5 days, whereas in squalestatin-treated neurons, the half-life of Aβ 42 was reduced to less than 24 hours ( Figure 1C ). Aβ 42 was not detected in cell supernatants, suggesting that the Aβ 42 had been digested rather than secreted from neurons. Experiments performed using synthetic Aβ showed that it behaved like the cell-derived Aβ 42 ; it had a half-life of greater than 5 days in untreated neurons and a much shorter half-life in squalestatintreated neurons ( Figure 1D) .
Similar results were obtained in neurons that had been treated with 1 μM simvastatin, a clinically approved hydroxymethyl glutaryl coenzyme A reductase inhibitor that also reduced cellular cholesterol levels. As cholesterol depletion has been demonstrated to affect the expression of some receptors, including the cellular prion protein [32] and acetylcholine receptors [33] , the possibility that it reduced the binding of Aβ 42 to neurons was explored. There were no significant differences in the amounts of cell-bound Aβ 42 between control and squalestatin-treated neurons, indicating that cholesterol depletion did not affect the binding of Aβ 42 to neurons ( Figure 1E) . In further studies, neurons were pulsed with 10 nM Aβ 42 ; after 2 days, 200 nM squalestatin was added, and cell extracts were collected 1 day later. The amount of Aβ 42 in squalestatin-treated neurons was significantly less than in mock-treated neurons ( Figure 1F ).
Squalestatin altered the distribution of Aβ 42 in neurons
Next, we looked at the distribution of Aβ 42 within neurons. In control neurons incubated with 10 nM Aβ 42 for 2 hours, most Aβ 42 was found within DRMs, observations that are consistent with reports that membranebound Aβ was recruited into lipid rafts [19] [20] [21] 34, 35] . In squalestatin-treated neurons, significantly less Aβ 42 was found within DRMs ( Figure 2A ). Since many of the proteins that are targeted to lipid rafts traffic via a recycling pathway that avoids the lysosomes [23, 36] , an organelle fractionation technique was used to examine the targeting of Aβ 42 to lysosomes. Organelles from neurons were separated on a density gradient, and lysosomes were identified by using immunoblots for lysosome-associated antigen 1 (LAMP-1), a marker of late endosomes/lysosomes. LAMP-1 was enriched within fractions 4 to 6, which were subsequently pooled to represent the lysosomes ( Figure 2B ). Firstly, we showed that treatment with 200 nM squalestatin did not affect the amount of the LAMP-1 found in neurons ( Figure 2C ). Next, treated neurons were incubated with 10 nM Aβ 42 for 2 hours, and the amount of Aβ 42 in lysosomes was measured. The amounts of Aβ 42 in lysosomes from squalestatin-treated neurons were significantly higher than the amounts of Aβ 42 in lysosomes from control neurons ( Figure 2D ).
Squalene reversed the effect of squalestatin on the cellular distribution of Aβ 42 One explanation of these results is that the squalestatininduced reduction in cholesterol disrupts the formation of lipid rafts that direct Aβ 42 into a pathway that avoids the lysosomes. This hypothesis was tested by incubating neurons with combinations of squalestatin and squalene. The addition of 5 μM squalene alone did not increase cholesterol concentrations above those of control cells (527 ng cholesterol/10 6 cells ± 28 to 519 ng ± 48, n = 6, P = 0.74), but the addition of 5 μM squalene reversed the effects of 200 nM squalestatin on cellular cholesterol concentrations (496 ng cholesterol/10 6 cells ± 45 to 369 ng ± 66, n = 6, P <0.05). The addition of 5 μM squalene also reversed the effects of 200 nM squalestatin on the trafficking of Aβ 42 ; the amount of Aβ 42 in DRMs was significantly lower and the amount in lysosomes significantly higher in neurons treated with squalestatin when compared with neurons treated with a combination of squalestatin and squalene (Table 1) . Furthermore, the effect of squalestatin on the degradation of Aβ 42 by neurons was reversed by the addition of squalene. When neurons incubated with 10 nM Aβ 42 for 2 days were subsequently treated with combinations of squalestatin and squalene for 24 hours, the amounts of Aβ 42 in neurons treated with 200 nM squalestatin and 5 μM squalene were significantly higher than in neurons treated with 200 nM squalestatin alone (8.9 nM Aβ 42 ± 0.8 compared with 2.4 nM Aβ 42 ± 0.6, n = 9, P <0.01).
Phospholipase A 2 and platelet-activating factor affect the degradation of Aβ 42 As Aβ activates cytoplasmic phospholipase A 2 (cPLA 2 ) [37] [38] [39] [40] , an enzyme that is implicated in tubule formation and intracellular trafficking [41] [42] [43] , specifically within the trans-Golgi network [44] , the effects of cPLA 2 inhibitors on Aβ 42 distribution were studied. Neurons were pulsed with 7PA2-CM containing 10 nM Aβ 42 for 2 hours and were washed, and cell extracts were collected at time points thereafter. Pre-treatment of neurons with cPLA 2 inhibitors (1 μM AACOCF 3 or MAFP) significantly reduced the half-life of Aβ 42 in neurons ( Figure 3A) . As the activation of cPLA 2 results in the production of prostaglandins and PAF, specific inhibitors/antagonists of these mediators were also tested. The half-life of Aβ 42 was reduced in neurons pre-treated with PAF receptor antagonists (1 μM ginkgolide B or 1 μM Hexa-PAF) ( Figure 3B ) but not in neurons pre-treated with cyclo-oxygenase inhibitors (1 μM aspirin or 2 μM ibuprofen) that reduce the production of prostaglandins. In neurons pre-treated with ginkgolide B or Hexa-PAF, the half-life of Aβ 42 was reduced to less than 24 hours. The addition of 1 μM Hexa-PAF to neurons that had been incubated with 10 nM Aβ 42 for 2 days resulted in the increased degradation of Aβ 42 ( Figure 3C ). Aβ 42 was not detected in the supernatants collected from either control or treated neurons, indicating that it was not secreted. Such results suggest that PAF, produced in response to Aβ 42 -induced activation of cPLA 2 , regulates the trafficking and hence the degradation of Aβ 42 in neurons. In support of this hypothesis, we found that the addition of 1 μM PAF reversed the effects of the cPLA 2 inhibitor (AACOCF 3 ) upon the degradation of Aβ 42 in neurons ( Figure 3D ). Experiments performed using synthetic Aβ showed that it had a half-life of approximately 24 hours in neurons pretreated with Hexa-PAF ( Figure 3E ).
Hexa-PAF altered the distribution of Aβ 42 in neurons
As the effects of Hexa-PAF on the neuronal degradation of Aβ 42 were similar to those of squalestatin, its effects upon cellular distribution of Aβ 42 were studied. After the addition of 10 nM Aβ 42 for 2 hours, we found no significant differences in the amounts of cell-associated Aβ 42 between control and Hexa-PAF-treated neurons (9.1 nM Aβ 42 ± 0.7 compared with 8.7 ± 1, n = 9, P = 0.32). However, pre-treatment of neurons with 1 μM Hexa-PAF or 1 μM ginkgolide B significantly reduced the amount of Aβ 42 found within DRMs ( Figure 4A ). Since the detergent solubility assay is a crude test of membrane targeting, neurons were incubated for 2 hours with 10 nM Aβ 42 and membranes were separated on sucrose density gradients. In control neurons, most of the Aβ 42 was found in lowdensity membrane fractions. In neurons pre-treated with 1 μM Hexa-PAF, less of the Aβ 42 was found within lowdensity fractions ( Figure 4B ). Although treatment with 1 μM Hexa-PAF did not affect the amount of the LAMP-1 found in neurons (Figure 4C ), the amounts of Aβ 42 in lysosomes from neurons pre-treated with Hexa-PAF or ginkgolide B were significantly higher than the amounts of Aβ 42 in lysosomes from control neurons ( Figure 4D ).
The effects of Hexa-PAF are not reversed by squalene
The similar effects of squalestatin and Hexa-PAF upon Aβ 42 trafficking suggested that Hexa-PAF may affect cholesterol synthesis. However, treatment with either 1 μM PAF or 1 μM Hexa-PAF did not significantly affect the amounts of cholesterol in neurons and the addition of 5 μM squalene did not reverse the effects of Hexa-PAF upon the targeting of Aβ 42 to DRMs or lysosomes (Table 2 ) nor alter the half-life of Aβ 42 in Hexa-PAFtreated neurons, indicating that Hexa-PAF did not affect cholesterol synthesis. Next, we explored the hypothesis that PAF increased cholesterol in specific cellular compartments. We sought to identify such compartments by separating organelles upon density gradients. PAF receptors were found in high concentrations in fractions 6 to 8 ( Figure 5A ), fractions that also contained Grp78, a marker of the ER. These fractions were subsequently pooled and incubated with or without PAF. The addition of 2 μM PAF caused a significant increase in cholesterol ( Figure 5B ). The PAF-induced increase in cholesterol in these fractions was not blocked by the inclusion of 200 nM squalestatin, indicating that PAF was not stimulating cholesterol synthesis. Conversely, the addition of PAF significantly reduced the amounts of cholesterol esters in ER fractions ( Figure 5C ).
Platelet-activating factor stimulates the release of cholesterol from stores of cholesterol esters
To determine the source of the PAF-induced increase in cholesterol, other methods of cholesterol regulation were explored. The amounts of cholesterol within cells is tightly controlled via a mixture of synthesis, uptake, and efflux and by esterification of cholesterol [45] . The cholesterol ester cycle involves the esterification of cholesterol by ACAT and the storage of cholesterol esters as cytoplasmic droplets [46] . Conversely, the hydrolysis of cholesterol esters results in the release of cholesterol from these stores. Thus, the cholesterol ester cycle helps maintain a constant level of cholesterol in cell membranes [46, 47] . Our findings that that both ACAT and CEH were concentrated in the ER fractions along with PAF receptors (Figure 6A ) suggested that PAF-induced activation of CEH released cholesterol. To explore the role of CEH in the trafficking of Aβ 42 , an inhibitor of CEH (DEUP) was used [48] . Treatment with 20 μM DEUP did not significantly affect total neuronal cholesterol levels (552 ng cholesterol ± 34 compared with 519 ng ± 48, n = 6, P = 0.26). However, pre-treatment of ER fractions with 20 μM DEUP blocked the PAF-induced increase in cholesterol ( Figure 6B ) and the PAF-induced reduction in cholesterol esters ( Figure 6C ). Pre-treatment of neurons with 20 μM DEUP did not alter the amount of Aβ 42 that bound to neurons, but reduced the amounts of Aβ 42 in DRMs and increased the amounts of Aβ 42 in lysosomes (Table 3) . As a consequence, the half-life of Aβ 42 in DEUP-treated cells was reduced to approximately 24 hours ( Figure 6D ). Pre-treatment of neurons with 20 μM DEUP also reduced the half-life of synthetic Aβ 1-42 to approximately 24 hours ( Figure 6E) . Notably, these effects of DEUP were not reversed by the inclusion of 5 μM squalene, indicating that they were not mediated by inhibition of cholesterol synthesis. Collectively these results suggest that CEH regulates the hydrolysis of cholesterol esters in the ER which is involved in the trafficking of Aβ 42 .
Discussion
This study showed that Aβ 42 taken up by cultured neurons was found predominantly within lipid rafts, traffics via a pathway that avoids the lysosomes and consequently was cleared slowly. We hypothesize that the slow clearance of Aβ 42 from neurons is a significant factor in the accumulation of Aβ 42 within the brain and leads to synapse damage and dementia in AD. Critically we show that these properties are dependent upon Aβ 42 induced activation of PLA 2 , the production of PAF, and the activation of CEH, the blockade of which alters the distribution of Aβ 42 in neurons and greatly increased its degradation.
This study used nanomolar concentrations of Aβ which did not affect the viability of neurons and which were similar to those found in the cerebrospinal fluid [49, 50] or in soluble brain extracts from patients with AD [51] [52] [53] . In control neurons, most of the Aβ was found within rafts, an observation consistent with reports that Aβ in the brain is found within cholesteroldense membrane rafts [19] [20] [21] . Reports that Aβ affects cellular cholesterol homeostasis [54] [55] [56] suggested that Aβ modifies the biochemistry of cell membranes and thus creates the rafts that are responsible for its trafficking. The targeting of Aβ 42 to rafts may have important biological consequences as many of the proteins that are targeted to rafts avoid the classic endocytic trafficking pathway that ends in the lysosomes [22, 57] . Our observations were compatible with Aβ 42 trafficking via a recycling pathway in neurons as little Aβ 42 was found within lysosomes and consequently Aβ 42 had a long half-life (over 5 days) in these neuronal cultures.
Here, we show that the trafficking of Aβ 42 within neurons could be affected by inhibiting cholesterol synthesis. Cholesterol has multiple effects upon cells, including altering membrane fluidity, protein trafficking, endocytosis, and exocytosis [58] . More specifically, cholesterol is important for the formation and function of membrane rafts, and in cholesterol-depleted neurons, most of the Aβ 42 was excluded from such rafts. Consequently, more Aβ 42 was found within lysosomes and the half-life of Aβ 42 was reduced from over 5 days in untreated neurons to less than 24 hours in squalestatin-treated neurons. Squalestatin was used because it inhibits squalene synthetase and reduces cholesterol production without affecting the production of the isoprenoids [27] . However, because squalestatin does not cross the blood-brain barrier, it does not have clinical application. Similar results were obtained in neurons treated with simvastatin, a cholesterol synthesis inhibitor that crosses the blood-brain barrier (data not shown). Simvastatin is widely used clinically and has been reported to reduce cholesterol levels within the brain [59, 60] .
Since cholesterol synthesis inhibitors affect many cholesterol-sensitive processes, we sought to find a compound with a more selective effect on rafts containing Aβ. Here, we showed that inhibitors of cPLA 2 , an enzyme that is implicated in tubule formation and intracellular trafficking [41] [42] [43] [44] , also affected Aβ 42 distribution. The activation of cPLA 2 is the first step in the production of PAF [61, 62] . PAF is produced in neurons incubated with Aβ 42 , and the amounts of PAF were elevated in both the temporal cortex of patients with AD and in murine AD models [63] . Our study suggested that the effects of cPLA 2 inhibitors on Aβ 42 distribution were mediated by a reduction in PAF production; not only did PAF antagonists have similar effects as cPLA 2 inhibitors, but PAF also reversed the effects of cPLA 2 inhibitors on Aβ 42 distribution and degradation.
Treating neurons with PLA 2 inhibitors, PAF antagonists, or PAF did not affect total cellular cholesterol concentrations, suggesting that these drugs did not affect cholesterol synthesis. PAF receptors were concentrated in the ER, and PAF increased cholesterol concentrations within ER fractions. Our studies are consistent with the hypothesis that local cholesterol concentrations within the ER affect the formation and functional rafts involved in the trafficking of Aβ 42 . Consequently, PAF antagonists had similar effects to squalestatin on the trafficking of Aβ 42 in that they reduced the amount of Aβ 42 within rafts. PAF is involved in endocytosis and endosome formation [64, 65] , and the blockade of PAF receptors may block the formation of endocytic structures involved in the trafficking or Aβ 42 . In neurons pre-treated with PAF receptor antagonists, more Aβ 42 was detected within lysosomes, sites of protein degradation [66] , and the halflife of Aβ 42 was reduced to less than 24 hours.
Notably, the PAF-induced increase in cholesterol was accompanied by reduced cholesterol esters, suggesting that cholesterol was being released from stores of cholesterol esters. The enzymes involved in the cholesterol ester cycle, ACAT and CEH, were also concentrated in the ER [67] , and the PAF-induced increase in cholesterol was blocked by inhibition of CEH. The role of CEH in Aβ 42 metabolism was demonstrated by using an inhibitor of CEH [48] , which greatly increased the degradation of Aβ 42 in a similar manner as PAF antagonists or squalestatin. Collectively these results indicate that PAF regulates the deacylation of cholesterol esters in the ER, freeing cholesterol that affects the formation and function of rafts which are involved in the trafficking of Aβ 42. Figure 7 Platelet-activating factor (PAF)-mediated hydrolysis of cholesterol esters stabilizes amyloid-beta (Aβ)-containing lipid rafts. Schematic demonstrating the putative mechanism regulating the formation of Aβ-containing rafts. In this theory, Aβ 42 activates cPLA 2 , resulting in the production of PAF. PAF activates cholesterol ester hydrolase (CEH) and the release of cholesterol from stores of cholesterol esters, which stabilizes Aβ 42 in rafts. Inhibition of cPLA 2 (arachidonyl trifluoromethyl ketone, or AACOCF 3 ), antagonism of the PAF receptors (Hexa-PAF), or inhibition of CEH (diethylumbelliferyl phosphate, is DEUP) reduces the cholesterol concentrations in the endoplasmic reticulum (ER). cPLA 2 , cPLA2 is cytoplasmic phospholipase A 2 ; Hexa-PAF, 1-O-hexadecyl-2-acetylsn-glycerol-3-phospho-(N,N,N-trimethyl)-hexanolamine.
Conclusions
In summary, these results support the hypothesis that Aβ 42 -induced activation of PLA 2 leads to the production of PAF which releases cholesterol from cholesterol esters. The cholesterol helps stabilize Aβ 42 in rafts which traffic via a recycling pathway that avoids the lysosomes. Thus, PAF receptor antagonists that reduce the release of cholesterol affect the rafts that direct Aβ 42 into the recycling pathway as summarized in Figure 7 . Consequently, in these neurons, the half-life of Aβ 42 was greatly reduced. In neurons treated with cholesterol synthesis inhibitors, PAF antagonists, or CEH inhibitors, the trafficking of Aβ 42 is altered so that Aβ 42 was found outside rafts, was targeted to lysosomes, and rapidly degraded. The novel observation that the activation of specific signaling pathways controls the trafficking and degradation of Aβ 42 may aid the development of drugs to delay the progression of AD. 
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